SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:
WX), a leading pharmaceutical, biotechnology and medical device research
and development outsourcing company with operations in China and the United
States, announced today that it has acquired a QPatch HT automated patch
clamp system, the first unit introduced into China by Sophion Bioscience.
The drug discovery process in pharmaceutical companies begins with
identifying potential targets for new diseases. One important class of
targets is ion channels that regulate the flow of ions across cellular
membranes and therefore influence the physiology of all cells. Patch clamp
is a widely applied gold-standard technique for the study of ion channels.
Speed and accuracy of automated patch clamp systems are heavily demanded by
pharmaceutical companies working with development of ion channel-based
The newly introduced QPatch HT is the world's first 48-channel gigaseal
patch clamp system that can be applied to both voltage-gated and
ligand-gated ion channels. With its ability to generate thousands of
high-quality data points daily, QPatch HT is enabling new screening
paradigms in ion channel drug discovery and safety testing on a truly
industrial basis. It is claimed to be taking automated patch clamping to a
new and even more powerful level.
"We hope the acquisition of the QPatch technology will assist WuXi
PharmaTech in expanding their services into the rapidly increasing fields
of cardiac safety testing and ion channel drug discovery," commented Frank
Henrichsen, Vice President Sales and Marketing in Sophion Bioscience, the
supplier of QPatch HT.
"We are very pleased to have installed the first QPatch HT automated
patch clamp system in China, and indeed, the first ever such unit in any
integrated drug and medical device R&D outsourcing service company," Dr.
Peng Wang, Vice President of Discovery Biology at WuXi PharmaTech, said
excitedly, "It will greatly enhance our drug R&D service capabilities and
productivity. We will continue investing in cutting-edge discovery
technologies as we strive to serve our global clients better."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company, with operations in China and the United
States. As a research-driven and customer-focused company, WuXi PharmaTech
provides pharmaceutical, biotechnology and medical device companies a broad
and integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi PharmaTech's
services are designed to assist its global partners in shortening the cycle
and lowering the cost of drug and medical device R&D. For more information,
please visit: http://www.wuxipharmatech.com .
SOURCE WuXi PharmaTech